MDS & Myeloproliferative Neoplasms

MDS & Myeloproliferative Neoplasms

A collection of features and news articles published in ASH Clinical News related to myelodysplastic syndromes and myeloproliferative neoplasms.

Mixed Results From SIMPLIFY-1 Complicate Myelofibrosis Treatment Decisions

The Janus kinase (JAK) inhibitor ruxolitinib is the only U.S. Food and Drug Administration–approved therapy for myelofibrosis (MF), but the resultant hematologic adverse events...

Eltrombopag Reduces Thrombocytopenic Events in Patients With AML and MDS, But Not as Much...

Compared with placebo, the oral thrombopoietic receptor agonist eltrombopag significantly lowered the incidence of thrombocytopenic events in patients with acute myeloid leukemia (AML) or...

Investigating a WT1 Peptide Vaccine in Patients With Acute Myeloid Leukemia

In an open-label, phase II study, treatment with galinpepimut-S (GPS) – a vaccine targeting the Wilms tumor 1 (WT1) protein – was well tolerated...

Teaching Old Drugs New Tricks?

When the U.S. Food and Drug Administration (FDA) approved CPX-351 (a fixed combination of daunorubicin and cytarabine), it appeared that everything old was new...

Newly Approved Drugs for AML: How to Use Them in Practice

In 2017, the U.S. Food and Drug Administration (FDA) approved several therapies for the treatment of hematologic malignancies, including four for acute myeloid leukemia...

Preliminary Results Show Flotetuzumab Well-Tolerated and Effective in Relapsed/Refractory AML and MDS

In early results from a phase I trial presented at the 2017 ASH Annual Meeting, researchers reported that the bispecific antibody flotetuzumab demonstrated anti-leukemic...

Examining the Risk of Cardiovascular Disease–Related Mortality in Patients With and MDS/CMML

Patients with chronic myelomonocytic leukemia (CMML) and myelodysplastic syndromes (MDS) have a higher risk of cardiovascular disease (CVD)–related mortality and cerebrovascular accident (CVA)–related mortality,...

Treating MRD With Azacitidine in Patients With High-Risk AML and MDS

For 58 percent of patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) at high risk for relapse, treatment of minimal residual disease...

Idasanutlin Well Tolerated in Patients With Polycythemia Vera and Essential Thrombocythemia

The MDM2 antagonist idasanutlin was well tolerated and demonstrated “clear clinical activity” in patients with polycythemia vera (PV) and essential thrombocythemia (ET) that was...

Momelotinib Trial in Myelofibrosis Fails to Meet Primary Endpoint

The Janus kinase (JAK) inhibitor ruxolitinib is the only treatment approved by the U.S. Food and Drug Administration for patients with myelofibrosis (MF), and...
Advertisement

Current Issue

January 2019 Annual Meeting Edition

This issue features highlights from the 2018 ASH Annual Meeting, including big data initiatives to improve prognosis in myelodysplastic syndromes, and more.